Expert Guidance for the Treatment of Myelofibrosis
Expert Guidance for the Treatment of Myelofibrosis

Released: May 08, 2023

About This Tool and Disclaimer

Clinical Care Options, LLC, is grateful to Prithviraj Bose, MD; John Mascarenhas, MD; Ruben A. Mesa, MD, FACP; Raajit Rampal, MD, PhD; and Brady L. Stein, MD, MHS, who provided expert guidance, knowledge, and support in the development of this Interactive Decision Support Tool.

Note: The current tool was created in February/March 2023 and reflects the guidelines available at that time.

The goal of the tool is to educate healthcare professionals on making optimal management choices for treating patients with myelofibrosis.

A series of questions allow the participant to select individual patient characteristics that are necessary to consider when making management choices. These characteristics include the presence of myelofibrosis symptoms, splenomegaly, or anemia, platelet count, prognostic risk group, and previous JAK inhibitor therapy.

It should be noted that these are not exclusive characteristics when selecting optimal treatment for patients with myelofibrosis. Other considerations that are not included in this tool, such as the presence of various comorbidities and any concurrent medications, also should be considered when appropriate for making management decisions.

For additional information on best practices in the management of patients with myelofibrosis, please follow this link for an online module authored by Prithviraj Bose, MD, and podcasts and commentaries by Prithviraj Bose, MD; Andrew Kuykendall, MD; John Mascarenhas, MD; Ruben A. Mesa, MD, FACP; Raajit Rampal, MD, PhD; and Brady L. Stein, MD, MHS.

This program is supported by educational grants from GSK, Incyte Corporation, and PharmaEssentia USA Corporation.

© 2023 Clinical Care Options, LLC. All rights reserved.

Access to and use of this Interactive Decision Support Tool titled, “Expert Guidance for the Treatment of Myelofibrosis” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices for patients with myelofibrosis. The information provided is based on the expert guidance of Prithviraj Bose, MD; John Mascarenhas, MD; Ruben A. Mesa, MD, FACP; Raajit Rampal, MD, PhD; and Brady L. Stein, MD, MHS.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Expert Guidance for the Treatment of Myelofibrosis” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights, are disclaimed.

Any trademarks are the property of respective companies.

© 2023 Clinical Care Options, LLC. All rights reserved.

Program Content